A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Three active treatment groups and a placebo group are planned. Randomization will be
sequential by dose level across the sites with placebo assignments randomly inserted. Each
subject's participation will be approximately 8 months, including screening, treatment
period, and a 3-month follow-up period.

Inclusion Criteria:

- Diagnosis of chronic schizophrenia that is clinically stable

- Body mass index (BMI) between 18.5 and 35.0 kg/m2, inclusive

- Stable antipsychotic medication regimen for >/= 2 months before Screening

- Be willing and able to be confined to an inpatient clinical research unit for a total
of 37 days during the course of the study

Exclusion Criteria:

- Aripiprazole used within 30 days before Screening

- History of intolerance of or allergy or hypersensitivity to aripiprazole, its
excipients, other antipsychotic agents, or INTRALIPID (including peanuts, soy, egg, or
glycerol)

- Current diagnosis of an Axis I disorder other than schizophrenia

- History of seizure disorder or any condition associated with seizures

- History of neuroleptic malignant syndrome (NMS)

- Positive test result for HIV, hepatitis B surface antigen, or anti-hepatitis C
antibodies

- Received medication by IM injection within 30 days before Screening

- Monoamine oxidase inhibitors (eg, phenelzine, tranylcypromine, selegiline) used within
30 days before Screening

- DSM-IV-TR diagnosis of alcohol or substance dependence, with the exception of nicotine
or caffeine dependence within 12 months before Screening

- Donation of blood or blood components within 4 weeks before Screening